IndexIQ Advisors’s Catalyst Pharmaceutical CPRX Stock Holding History

IndexIQ Advisors’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$421K	Sell	50,802 -40,805	-45%	-$288K	0.01%	452
2021 Q4	$620K	Sell	91,607 -5,920	-6%	-$38.9K	0.02%	435
2021 Q3	$517K	Buy	97,527 +9,769	+11%	+$53.4K	0.02%	526
2021 Q2	$505K	Sell	87,758 -4,721	-5%	-$24.4K	0.02%	457
2021 Q1	$426K	Buy	92,479 +38,077	+70%	+$151K	0.02%	429
2020 Q4	$182K	Buy	54,402 +5,617	+12%	+$18.9K	0.01%	935
2020 Q3	$145K	Buy	48,785 +2,646	+6%	+$10.3K	0.01%	854
2020 Q2	$213K	Sell	46,139 -2,077	-4%	-$9.33K	0.01%	505
2020 Q1	$186K	Buy	+48,216	New	+$198K	0.01%	534

Other funds holding CPRX

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return

IndexIQ Advisors's CPRX Position: Q1 2022 in Review

IndexIQ Advisors reduced its Catalyst Pharmaceutical (CPRX) stake by 45% in Q1 2022, selling an estimated $288K and leaving 50,802 shares worth $421K. The position accounts for 0.01% of the portfolio, ranked #452.

IndexIQ Advisors first reported a position in CPRX in Q1 2020 and has held it in 9 quarters since. The position peaked at $620K in Q4 2021. 187 funds tracked by Wall St. Rank hold CPRX as of Q1 2022.

IndexIQ Advisors held 50,802 shares of Catalyst Pharmaceutical worth $421K as of Q1 2022.
IndexIQ Advisors sold 40,805 Catalyst Pharmaceutical shares in Q1 2022, an estimated $288K.
Catalyst Pharmaceutical made up 0.01% of IndexIQ Advisors's portfolio in Q1 2022, its #452 holding.
IndexIQ Advisors first reported a position in Catalyst Pharmaceutical in Q1 2020 and has held it in 9 quarters since.
IndexIQ Advisors's Catalyst Pharmaceutical position peaked at $620K in Q4 2021.
187 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2022.

Based on IndexIQ Advisors's 13F filing for Q1 2022, filed 6 May 2022.